Page Title
Clinical Trial Finder
Ask About Participating in This Study
Restore CFTR ProteinCompleted with Results
Study to evaluate VX-561 in adults 18 years and older with cystic fibrosis, protocol number Vertex VX-561-101The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Restore CFTR ProteinCompleted with Results
Study to evaluate VX-561 in adults 18 years and older with cystic fibrosis, protocol number Vertex VX-561-101
This study evaluated different doses of the drug VX-561 to determine safety and effectiveness. VX-561 is a modification of ivacaftor and was being studied to determine if it can replace ivacaftor and be taken one time per day rather than the current ivacaftor dosing regimen of twice daily.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 100%
-
Number of Visits:
8
-
Length of Participation:
16 weeks
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More